» Articles » PMID: 31759383

Comparison of MicroFlow Imaging with Color and Power Doppler Imaging for Detecting and Characterizing Blood Flow Signals in Hepatocellular Carcinoma

Overview
Journal Ultrasonography
Date 2019 Nov 25
PMID 31759383
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The purpose of this study was to compare the sensitivity of MicroFlow Imaging (MFI) with that of color and power Doppler imaging (CDI and PDI, respectively) in detecting the vascularity of hepatocellular carcinomas (HCCs).

Methods: This prospective study enrolled 51 patients diagnosed with HCC between August 2018 and December 2018. CDI, PDI, MFI, and contrast-enhanced ultrasound (CEUS) were performed. Two radiologists evaluated the presence and pattern of tumoral vascularity on CDI, PDI, and MFI. Vascular presence was graded on a 5-point scale (0, absent; 4, >50% of the tumor). The vascular pattern was chosen from following categories: basket, vessels in tumor, spot, detouring, mixed, or others. Two additional radiologists assessed CEUS images for the presence and pattern of tumoral vascularity, which served as the reference standard. If the tumoral vascular pattern on each examination matched that of the CEUS images, the Wilcoxon test and McNemar test, respectively, were used to compare the sensitivity for detecting tumoral vascularity between MFI and CDI, and between MFI and PDI. Logistic regression analysis was performed to identify factors associated with MFI detectability of tumoral vascularity.

Results: CEUS demonstrated tumoral vascularity in 98.0% (50 of 51) of patients. MFI (58.0%, 29 of 50) demonstrated a higher sensitivity than CDI (14.0%, 7 of 50) or PDI (14.0%, 7 of 50) (P<0.001 for both) in detecting tumoral vascularity, provided that the vascular pattern was correctly depicted. Only tumor depth was associated with the MFI detectability of tumoral vascularity.

Conclusion: The sensitivity of MFI was higher than that of CDI or PDI in detecting the vascularity of HCCs when the vascular pattern was considered. MFI better detected the vascularity of shallow tumors.

Citing Articles

Reply to Letter to the Editor: Enhancing methodological rigor in the evaluation of microvascular flow imaging for recurrent thyroid cancer.

Suh P, Baek J, Lee J, Chung S, Choi Y, Chung K Eur Radiol. 2024; 35(2):610-611.

PMID: 39466395 DOI: 10.1007/s00330-024-11113-8.


Letter to the editor, "Superb microvascular ultrasound is a promising non-invasive diagnostic tool to assess a ventriculoperitoneal shunt system function: a feasibility study".

Abdul Sattar A, Hamza M, Jalil Z Neurosurg Rev. 2024; 47(1):787.

PMID: 39394464 DOI: 10.1007/s10143-024-03027-2.


Comparison of micro-flow imaging and contrast-enhanced ultrasonography in assessing segmental congestion after right living donor liver transplantation.

Han T, Jeong W, Shin J, Cha D, Gu K, Rhu J Ultrasonography. 2024; 43(6):469-477.

PMID: 39390717 PMC: 11532526. DOI: 10.14366/usg.24114.


Human-Sized Organ Machine Perfusion: A Systematic Review on the Added Value of Medical Imaging for Organ Condition Assessment.

Van Der Hoek J, Krommendijk M, Manohar S, Arens J, Groot Jebbink E Transpl Int. 2024; 37:12827.

PMID: 39296469 PMC: 11408214. DOI: 10.3389/ti.2024.12827.


Use superb microvascular imaging to diagnose and predict metastatic cervical lymph nodes in patients with papillary thyroid carcinoma.

Huang T, Huang P, Luo Z, Lv J, Jin P, Zhang T J Cancer Res Clin Oncol. 2024; 150(5):268.

PMID: 38772976 PMC: 11108919. DOI: 10.1007/s00432-024-05770-x.


References
1.
Bartolotta T, Taibbi A, Midiri M, Lagalla R . Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?. Ultrasonography. 2019; 38(3):200-214. PMC: 6595127. DOI: 10.14366/usg.18060. View

2.
Oosterveld B, Thijssen J, Hartman P, Romijn R, Rosenbusch G . Ultrasound attenuation and texture analysis of diffuse liver disease: methods and preliminary results. Phys Med Biol. 1991; 36(8):1039-64. DOI: 10.1088/0031-9155/36/8/002. View

3.
. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 2019; 13(3):227-299. PMC: 6529163. DOI: 10.5009/gnl19024. View

4.
Lencioni R, Pinto F, Armillotta N, Bartolozzi C . Assessment of tumor vascularity in hepatocellular carcinoma: comparison of power Doppler US and color Doppler US. Radiology. 1996; 201(2):353-8. DOI: 10.1148/radiology.201.2.8888222. View

5.
Gleeson T, Bulugahapitiya S . Contrast-induced nephropathy. AJR Am J Roentgenol. 2004; 183(6):1673-89. DOI: 10.2214/ajr.183.6.01831673. View